World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF THYROID CANCER USING SIMILAR MOLECULE- VANDETANIB FUMARATE

Dr. Syed Ahmed Hussain*, Nazneen, Faheem Unnisa, Arshiya Tarannum, Umaima Batool Osmani, Raheem Unnisa Shaik and Maimuna Fatima

ABSTRACT

Aim: The aim of this study is to explore the efficacy of Vandetanib Fumarate as a potential therapeutic alternative
for thyroid cancer treatment by comparing its cytotoxicity and cell viability results against the standard drug,
Lenvatinib. Objective: The primary objective is to evaluate Vandetanib Fumarate's cell viability using five
different assays: MTT, CellTiter-Glo Luminescent, Alamar Blue, SRB, and LDH Cytotoxicity Assays. The
secondary objective is to analyze the performance of Vandetanib Fumarate in various concentrations and assess its
potential as an alternative treatment. Research: Cytotoxicity studies were conducted on kidney cancer cell lines,
comparing Vandetanib Fumarate at concentrations of 1 μM, 5 μM, and 10 μM against the control drug, Lenvatinib.
The results demonstrated a dose-dependent decrease in cell viability across all five assays, indicating Vandetanib
Fumarate's effectiveness. Conclusion: Vandetanib Fumarate exhibited significant cytotoxicity and reduced cell
viability compared to Lenvatinib, particularly at higher concentrations. This suggests that Vandetanib Fumarate
may serve as a viable therapeutic candidate for further investigation in thyroid cancer treatment.

[Full Text Article]   [Download Certificate]